The largest randomized controlled trial of leading longevity drug is underway

13 hours ago

A new clinical trial at the University of Arizona is the largest and longest randomized controlled trial of low-dose rapamycin in healthy older adults to date.
Rapamycin, historically used as an immunosuppressant for transplant patients, is being re-evaluated as a modulator of aging pathways at low doses.
The trial will involve 720 participants aged 65+ and will administer 8 mg of rapamycin once weekly for two years, followed by one year of follow-up.
Primary endpoints include transition from pre-frail to frail state and reduction in IL-6 levels to measure impact on aging-related inflammation.
An extensive biomarker panel will assess epigenetic age, immune function, metabolic health, and physical function.
Preliminary pharmacokinetic studies in 50 participants confirmed safety, with trough levels below immunosuppressive thresholds and no significant adverse events.
The trial aims to determine if rapamycin slows biological aging and improves healthspan, addressing long-term safety and heterogeneity of response.

Hasty Briefsbeta